SCHEMBL4079863

SCHEMBL4079863

CCOC(=O)c1c(NC(=O)C2CC3CCC2C3)sc2c1CCOC2

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 7/20 0.72
MAPT P10636 4/20 0.53
ALDH1A1 P00352 4/20 0.53
LMNA P02545 2/20 0.53
HTT P42858 1/20 0.52
KMT2A Q03164 1/20 0.50
CNR1 P21554 1/20 0.48
KDM4E B2RXH2 3/20 0.46
POLB P06746 2/20 0.46
GAA P10253 1/20 0.46
TSHR P16473 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ALOX15 P16050 1/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
HPGD P15428 1/20 0.45
BLM P54132 1/20 0.45
TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5460031 0.86 MAPT (0.56) CNR2MAPTALDH1A1LMNAHTT
SCHEMBL4090344 0.85 CNR2 (0.72) CNR2HTTKMT2ACNR1GAA
SCHEMBL4080262 0.84 CNR2 (1.00) CNR2CNR1
SCHEMBL5450569 0.84 KMT2A (0.69) CNR2MAPTALDH1A1LMNAHTT
SCHEMBL5453100 0.82 CNR2 (0.67) CNR2MAPTALDH1A1LMNAHTT
SCHEMBL5460238 0.82 CNR2 (0.64) CNR2MAPTALDH1A1LMNAHTT
SCHEMBL4094543 0.81 CNR2 (0.66) CNR2MAPTALDH1A1LMNAHTT
SCHEMBL5450611 0.81 CNR2 (0.66) CNR2MAPTALDH1A1LMNAHTT
SCHEMBL4080930 0.81 CNR2 (0.69) CNR2MAPTALDH1A1LMNAHTT
SCHEMBL5460524 0.80 ALDH1A1 (0.56) CNR2MAPTALDH1A1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338623-B2 N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants ABBVIE INC. (US) 2012-12-25 US disclosed
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 CNR2 2/4885MAPT 2527/4885ALDH1A1 1504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.